{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T13:20:41Z","timestamp":1790256041266,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T00:00:00Z","timestamp":1754352000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cost Eff Resour Alloc"],"DOI":"10.1186\/s12962-025-00647-3","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T11:18:39Z","timestamp":1754392719000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Pioneering SMA therapies for all types: survival gains, cost dynamics, and performance-based agreements"],"prefix":"10.1186","volume":"23","author":[{"given":"Ahmed","family":"Al-jedai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajer","family":"Al-Mudaiheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AlJohara","family":"AlSakran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fahad A.","family":"Bashiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Ghamdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad A.","family":"Almuhaizea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdulaziz","family":"AlSamman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Ojeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,5]]},"reference":[{"issue":"11","key":"647_CR1","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1093\/hmg\/6.11.1961","volume":"6","author":"G Battaglia","year":"1997","unstructured":"Battaglia G, Princivalle A, Forti F, Lizier C, Zeviani M. Expression of the SMN gene, the spinal muscular atrophy determining gene, in the mammalian central nervous system. Hum Mol Genet. 1997;6(11):1961\u201371.","journal-title":"Hum Mol Genet"},{"issue":"4","key":"647_CR2","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.ncl.2015.07.004","volume":"33","author":"SJ Kolb","year":"2015","unstructured":"Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831\u201346.","journal-title":"Neurol Clin"},{"issue":"15","key":"647_CR3","doi-asserted-by":"publisher","first-page":"11939","DOI":"10.3390\/ijms241511939","volume":"24","author":"H Nishio","year":"2023","unstructured":"Nishio H, Niba ETE, Saito T, Okamoto K, Takeshima Y, Awano H. Spinal muscular atrophy: the past, present, and future of diagnosis and treatment. IJMS. 2023;24(15):11939.","journal-title":"IJMS"},{"issue":"4","key":"647_CR4","first-page":"499","volume":"5","author":"M Oskoui","year":"2008","unstructured":"Oskoui M, Kaufmann P. Spinal Muscular Atrophy Neurother. 2008;5(4):499\u2013506.","journal-title":"Spinal Muscular Atrophy Neurother"},{"issue":"3","key":"647_CR5","first-page":"299","volume":"1860","author":"RN Singh","year":"2017","unstructured":"Singh RN, Howell MD, Ottesen EW, Singh NN. Diverse role of survival motor neuron protein. Biochimica et biophysica acta (BBA) -. Gene Regul Mech. 2017;1860(3):299\u2013315.","journal-title":"Gene Regul Mech"},{"issue":"1","key":"647_CR6","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-017-0671-8","volume":"12","author":"IEC Verhaart","year":"2017","unstructured":"Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2013 a literature review. Orphanet J Rare Dis. 2017;12(1):124.","journal-title":"Orphanet J Rare Dis"},{"issue":"2","key":"647_CR7","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1007\/s13311-014-0314-x","volume":"12","author":"MA Farrar","year":"2015","unstructured":"Farrar MA, Kiernan MC. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics. 2015;12(2):290\u2013302.","journal-title":"Neurotherapeutics"},{"issue":"1","key":"647_CR8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.neuron.2016.12.029","volume":"93","author":"NJ Kramer","year":"2017","unstructured":"Kramer NJ, Gitler AD. Raise the roof: boosting the efficacy of a spinal muscular atrophy therapy. Neuron. 2017;93(1):3\u20135.","journal-title":"Neuron"},{"key":"647_CR9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.2147\/TACG.S239603","volume":"14","author":"MC Keinath","year":"2021","unstructured":"Keinath MC, Prior DE, Prior TW. Spinal muscular atrophy: mutations, testing, and clinical relevance. TACG. 2021;14:11\u201325.","journal-title":"TACG"},{"issue":"6","key":"647_CR10","doi-asserted-by":"publisher","first-page":"826","DOI":"10.4187\/respcare.05250","volume":"62","author":"HB Panitch","year":"2017","unstructured":"Panitch HB. Respiratory implications of pediatric neuromuscular disease. Respir Care. 2017;62(6):826\u201348.","journal-title":"Respir Care"},{"key":"647_CR11","doi-asserted-by":"crossref","unstructured":"Manzur AY, Muntoni F, Simonds A. February. Muscular Dystrophy Campaign sponsored workshop: Recommendation for Respiratory Care of Children with Spinal Muscular Atrophy Type II and III. 13th 2002, London, UK. Neuromuscular Disorders. 2003;13(2):184\u20139.","DOI":"10.1016\/S0960-8966(02)00212-2"},{"key":"647_CR12","doi-asserted-by":"publisher","unstructured":"Butchbach MER. Copy Number Variations in the Survival Motor Neuron Genes: Implications for Spinal Muscular Atrophy and Other Neurodegenerative Diseases. Front Mol Biosci [Internet]. 2016 Mar 10 [cited 2024 Feb 1];3. Available from: http:\/\/journal.frontiersin.org\/Article\/https:\/\/doi.org\/10.3389\/fmolb.2016.00007\/abstract","DOI":"10.3389\/fmolb.2016.00007\/abstract"},{"issue":"5","key":"647_CR13","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1001\/archneur.1995.00540290108025","volume":"52","author":"K Zerres","year":"1995","unstructured":"Zerres K. Natural history in proximal spinal muscular atrophy: clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518.","journal-title":"Arch Neurol"},{"issue":"11","key":"647_CR14","doi-asserted-by":"publisher","first-page":"e2049","DOI":"10.1002\/mgg3.2049","volume":"10","author":"M Al Jumah","year":"2022","unstructured":"Al Jumah M, Al Rajeh S, Eyaid W, Al-Jedai A, Al Mudaiheem H, Al Shehri A, et al. Spinal muscular atrophy carrier frequency in Saudi Arabia. Molec Gen Gen Med. 2022;10(11):e2049.","journal-title":"Molec Gen Gen Med"},{"issue":"3","key":"647_CR15","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ejpn.2019.03.004","volume":"23","author":"E Landfeldt","year":"2019","unstructured":"Landfeldt E, Edstr\u00f6m J, Sejersen T, Tulinius M, Lochm\u00fcller H, Kirschner J. Quality of life of patients with spinal muscular atrophy: A systematic review. Eur J Pediatr Neurol. 2019;23(3):347\u201356.","journal-title":"Eur J Pediatr Neurol"},{"issue":"1","key":"647_CR16","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s13023-021-01695-7","volume":"16","author":"T Dangouloff","year":"2021","unstructured":"Dangouloff T, Botty C, Beaudart C, Servais L, Hiligsmann M. Systematic literature review of the economic burden of spinal muscular atrophy and economic evaluations of treatments. Orphanet J Rare Dis. 2021;16(1):47.","journal-title":"Orphanet J Rare Dis"},{"issue":"12","key":"647_CR17","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1007\/s40263-021-00878-x","volume":"35","author":"SM Hoy","year":"2021","unstructured":"Hoy SM, Nusinersen. A review in 5q spinal muscular atrophy. CNS Drugs. 2021;35(12):1317\u201328.","journal-title":"CNS Drugs"},{"issue":"3","key":"647_CR18","first-page":"194","volume":"24","author":"EE Neil","year":"2019","unstructured":"Neil EE, Bisaccia EK. Nusinersen: A novel antisense oligonucleotide for the treatment of spinal muscular atrophy. J Pediatr Pharmacol Ther. 2019;24(3):194\u2013203.","journal-title":"J Pediatr Pharmacol Ther"},{"key":"647_CR19","doi-asserted-by":"publisher","first-page":"942976","DOI":"10.3389\/fncel.2022.942976","volume":"16","author":"J Qiu","year":"2022","unstructured":"Qiu J, Wu L, Qu R, Jiang T, Bai J, Sheng L, et al. History of development of the life-saving drug Nusinersen in spinal muscular atrophy. Front Cell Neurosci. 2022;16:942976.","journal-title":"Front Cell Neurosci"},{"issue":"3","key":"647_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.4103\/ijabmr.IJABMR_190_19","volume":"9","author":"R Mahajan","year":"2019","unstructured":"Mahajan R. Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever. Int J App Basic Med Res. 2019;9(3):127.","journal-title":"Int J App Basic Med Res"},{"issue":"9","key":"647_CR21","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1080\/14712598.2022.2066471","volume":"22","author":"HJ McMillan","year":"2022","unstructured":"McMillan HJ, Proud CM, Farrar MA, Alexander IE, Muntoni F, Servais L. Onasemnogene abeparvovec for the treatment of spinal muscular atrophy. Expert Opin Biol Ther. 2022;22(9):1075\u201390.","journal-title":"Expert Opin Biol Ther"},{"key":"647_CR22","doi-asserted-by":"crossref","unstructured":"Kakazu J, Walker NL, Babin KC, Trettin KA, Lee C, Sutker PB et al. Risdiplam for the Use of Spinal Muscular Atrophy. Orthopedic Reviews [Internet]. 2021 Jul 12 [cited 2024 Jan 8];13(2). Available from: https:\/\/orthopedicreviews.openmedicalpublishing.org\/article\/25579-risdiplam-for-the-use-of-spinal-muscular-atrophy","DOI":"10.52965\/001c.25579"},{"issue":"18","key":"647_CR23","doi-asserted-by":"publisher","first-page":"1713","DOI":"10.1056\/NEJMoa1706198","volume":"377","author":"JR Mendell","year":"2017","unstructured":"Mendell JR, Al-Zaidy S, Shell R, Arnold WD, Rodino-Klapac LR, Prior TW, et al. Single-Dose Gene-Replacement therapy for spinal muscular atrophy. N Engl J Med. 2017;377(18):1713\u201322.","journal-title":"N Engl J Med"},{"issue":"10063","key":"647_CR24","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J, Day JW, Montes J, De Vivo DC, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2016;388(10063):3017\u201326.","journal-title":"Lancet"},{"issue":"1","key":"647_CR25","doi-asserted-by":"publisher","first-page":"1601484","DOI":"10.1080\/20016689.2019.1601484","volume":"7","author":"DC Malone","year":"2019","unstructured":"Malone DC, Dean R, Arjunji R, Jensen I, Cyr P, Miller B, et al. Cost-effectiveness analysis of using onasemnogene Abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients. J Market Access Health Policy. 2019;7(1):1601484.","journal-title":"J Market Access Health Policy"},{"issue":"2","key":"647_CR26","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.nmd.2015.10.006","volume":"26","author":"E Mercuri","year":"2016","unstructured":"Mercuri E, Finkel R, Montes J, Mazzone ES, Sormani MP, Main M, et al. Patterns of disease progression in type 2 and 3 SMA: implications for clinical trials. Neuromuscul Disord. 2016;26(2):126\u201331.","journal-title":"Neuromuscul Disord"},{"issue":"3","key":"647_CR27","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1152\/ajplegacy.1975.229.3.754","volume":"229","author":"IC Ehrhart","year":"1975","unstructured":"Ehrhart IC, Parker PE, Weidner WJ, Dabney JM, Scott JB, Haddy FJ. Coronary vascular and myocardial responses to carotid body stimulation in the dog. Am J Physiol. 1975;229(3):754\u201360.","journal-title":"Am J Physiol"},{"key":"647_CR28","doi-asserted-by":"publisher","unstructured":"Baranello G, Servais L, Masson R, Mazurkiewicz-Be\u0142dzi\u0144ska M, Rose K, Vlodavets D et al. FIREFISH Part 2: Efficacy and safety of risdiplam (RG7916) in infants with Type 1 spinal muscular atrophy (SMA). In: Paediatric respiratory physiology and sleep [Internet]. European Respiratory Society; 2020 [cited 2024 Feb 1]. p. 1172. Available from: http:\/\/erj.ersjournals.com\/lookup\/doi\/https:\/\/doi.org\/10.1183\/13993003.congress-2020.1172","DOI":"10.1183\/13993003.congress-2020.1172"},{"issue":"2","key":"647_CR29","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/pst.514","volume":"11","author":"Q Gong","year":"2012","unstructured":"Gong Q, Fang L. Asymptotic properties of mean survival estimate based on the Kaplan-Meier curve with an extrapolated tail. Pharm Stat. 2012;11(2):135\u201340.","journal-title":"Pharm Stat"},{"issue":"1","key":"647_CR30","doi-asserted-by":"publisher","first-page":"e000094","DOI":"10.1136\/bmjmed-2021-000094","volume":"1","author":"NR Latimer","year":"2022","unstructured":"Latimer NR, Adler AI. Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness. BMJ Med. 2022;1(1):e000094.","journal-title":"BMJ Med"},{"issue":"1","key":"647_CR31","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0022-510X(96)00284-5","volume":"146","author":"K Zerres","year":"1997","unstructured":"Zerres K, Rudnik-Sch\u00f6neborn S, Forrest E, Lusakowska A, Borkowska J, Hausmanowa-Petrusewicz I. A collaborative study on the natural history of childhood and juvenile onset proximal spinal muscular atrophy (type II and III SMA): 569 patients. J Neurol Sci. 1997;146(1):67\u201372.","journal-title":"J Neurol Sci"},{"issue":"10","key":"647_CR32","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.3390\/brainsci13101446","volume":"13","author":"S Crisafulli","year":"2023","unstructured":"Crisafulli S, Boccanegra B, Vitturi G, Trifir\u00f2 G, De Luca A. Pharmacological therapies of spinal muscular atrophy: A narrative review of preclinical, Clinical\u2013Experimental, and Real-World evidence. Brain Sci. 2023;13(10):1446.","journal-title":"Brain Sci"},{"issue":"10","key":"647_CR33","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/brainsci13101419","volume":"13","author":"Y Qiao","year":"2023","unstructured":"Qiao Y, Chi Y, Gu J, Ma Y. Safety and efficacy of Nusinersen and Risdiplam for spinal muscular atrophy: A systematic review and Meta-Analysis of randomized controlled trials. Brain Sci. 2023;13(10):1419.","journal-title":"Brain Sci"},{"key":"647_CR34","doi-asserted-by":"crossref","unstructured":"Servais L, Day JW, De Vivo DC, Kirschner J, Mercuri E, Muntoni F et al. Real-World outcomes in patients with spinal muscular atrophy treated with onasemnogene abeparvovec monotherapy: findings from the RESTORE registry. JND. 2024;1\u201318.","DOI":"10.3233\/JND-230122"},{"issue":"1","key":"647_CR35","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/healthcare12010119","volume":"12","author":"P Hospodkov\u00e1","year":"2024","unstructured":"Hospodkov\u00e1 P, Kar\u00e1sek P, Tichop\u00e1d A. Stakeholder insights into Czech Performance-Based managed entry agreements: potential for transformative change in pharmaceutical access?? Healthcare. 2024;12(1):119.","journal-title":"Healthcare"},{"issue":"4","key":"647_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/j.jval.2019.12.008","volume":"23","author":"M Dabbous","year":"2020","unstructured":"Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: policy analysis from the European perspective. Value Health. 2020;23(4):425\u201333.","journal-title":"Value Health"},{"issue":"1","key":"647_CR37","doi-asserted-by":"publisher","first-page":"e83","DOI":"10.1017\/S026646232100057X","volume":"37","author":"HG Eichler","year":"2021","unstructured":"Eichler HG, Adams R, Andreassen E, Arlett P, Van De Casteele M, Chapman SJ, et al. Exploring the opportunities for alignment of regulatory postauthorization requirements and data required for performance-based managed entry agreements. Int J Technol Assess Health Care. 2021;37(1):e83.","journal-title":"Int J Technol Assess Health Care"},{"key":"647_CR38","unstructured":"MacDuffie KE, Cohn B, Appelbaum P, Brothers KB, Doherty D, Goldenberg AJ et al. Early Intervention services in the era of genomic medicine: setting a research agenda. Pediatr Res [Internet]. 2024 Oct 22 [cited 2025 May 22]; Available from: https:\/\/www.nature.com\/articles\/s41390-024-03668-5"},{"issue":"6","key":"647_CR39","doi-asserted-by":"publisher","first-page":"fcac269","DOI":"10.1093\/braincomms\/fcac269","volume":"4","author":"FEV Scheijmans","year":"2022","unstructured":"Scheijmans FEV, Cuppen I, van Eijk RPA, Wijngaarde CA, Schoenmakers MAGC, van der Woude DR, et al. Population-based assessment of Nusinersen efficacy in children with spinal muscular atrophy: a 3-year follow-up study. Brain Commun. 2022;4(6):fcac269.","journal-title":"Brain Commun"},{"issue":"3","key":"647_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.3390\/ijns8030045","volume":"8","author":"STF Shih","year":"2022","unstructured":"Shih STF, Keller E, Wiley V, Farrar MA, Wong M, Chambers GM. Modelling the Cost-Effectiveness and budget impact of a newborn screening program for spinal muscular atrophy and severe combined immunodeficiency. Int J Neonatal Screen. 2022;8(3):45.","journal-title":"Int J Neonatal Screen"}],"container-title":["Cost Effectiveness and Resource Allocation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00647-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12962-025-00647-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12962-025-00647-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:46:45Z","timestamp":1757357205000},"score":1,"resource":{"primary":{"URL":"https:\/\/resource-allocation.biomedcentral.com\/articles\/10.1186\/s12962-025-00647-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["647"],"URL":"https:\/\/doi.org\/10.1186\/s12962-025-00647-3","relation":{},"ISSN":["1478-7547"],"issn-type":[{"value":"1478-7547","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,5]]},"assertion":[{"value":"10 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No potential competing interest was reported by the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}